Literature DB >> 15882559

Synovitis: a potential predictive factor of structural progression of medial tibiofemoral knee osteoarthritis -- results of a 1 year longitudinal arthroscopic study in 422 patients.

X Ayral1, E H Pickering, T G Woodworth, N Mackillop, M Dougados.   

Abstract

OBJECTIVE: To evaluate the prevalence of synovitis in painful medial tibiofemoral knee osteoarthritis (OA) and to evaluate correlation between synovitis and the structural severity and progression of tibiofemoral cartilage damage. STUDY: Multicenter, longitudinal, 1-year duration. PATIENTS: Primary painful knee OA (ACR criteria) of the medial tibiofemoral compartment, with pain of the signal knee on at least 30 days in the past 2 months, medial joint space width > or = 2mm, at least 10% of one cartilage surface of the medial compartment affected by superficial fibrillation or worse at baseline arthroscopy. ARTHROSCOPIC PARAMETERS: Knee arthroscopy under local anesthesia was performed and videorecorded at entry and after 1 year. Medial chondropathy was scored by using Societe Francaise d'Arthroscopie (SFA) score (0-100) and reader's overall assessment (VAS score, 100 mm). Progression of medial chondropathy was defined by a change in SFA and VAS scores over 4.5 and 8.0 mm after 1 year, respectively. Medial perimeniscal synovium was scored as normal (few translucent and slender villi, fine vascular network), reactive (proliferation of opaque villi), or inflammatory (hypervascularization and/or proliferation of hypertrophic and hyperemic villi). Medial chondropathy and synovitis were scored by a single reader blind to chronology of paired videotapes.
RESULTS: Four hundred and twenty-two patients were enrolled (mean age: 61 years, females: 59%, body mass index: 31, mean disease duration: 4 years) and completed the 1-year study. Synovial abnormalities were present in 50% of the patients with reactive and inflammatory aspects in 29% and 21% of the patients, respectively. Patients with a reactive or inflammatory medial synovium had a more severe medial chondropathy. The worsening in medial chondropathy after 1 year was statistically more severe in the group of patients with an inflammatory perimeniscal synovial membrane at baseline compared to patients with normal and reactive aspects, with no difference between these two latter groups. The odds ratio for progression in VAS score after 1 year was 3.11 (95% CI [1.07, 5.69]) for patients with inflammatory synovium at baseline compared to patients with normal synovium.
CONCLUSIONS: This study suggests that abnormalities of the medial perimeniscal synovium are a common feature of painful medial knee OA, associated with more severe medial chondropathy. It also suggests that an inflammatory aspect of the medial perimeniscal synovium could be considered as a predictive factor of subsequent increased degradation of medial chondropathy.

Entities:  

Mesh:

Year:  2005        PMID: 15882559     DOI: 10.1016/j.joca.2005.01.005

Source DB:  PubMed          Journal:  Osteoarthritis Cartilage        ISSN: 1063-4584            Impact factor:   6.576


  187 in total

Review 1.  The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis.

Authors:  Jérémie Sellam; Francis Berenbaum
Journal:  Nat Rev Rheumatol       Date:  2010-10-05       Impact factor: 20.543

2.  Synovial inflammation in patients undergoing arthroscopic meniscectomy: molecular characterization and relationship to symptoms.

Authors:  Carla R Scanzello; Brian McKeon; Bryan H Swaim; Edward DiCarlo; Eva U Asomugha; Veero Kanda; Anjali Nair; David M Lee; John C Richmond; Jeffrey N Katz; Mary K Crow; Steven R Goldring
Journal:  Arthritis Rheum       Date:  2011-02

Review 3.  Osteoarthritis: a disease of the joint as an organ.

Authors:  Richard F Loeser; Steven R Goldring; Carla R Scanzello; Mary B Goldring
Journal:  Arthritis Rheum       Date:  2012-03-05

4.  Correlations between both the expression levels of inflammatory mediators and growth factor in medial perimeniscal synovial tissue and the severity of medial knee osteoarthritis.

Authors:  Liang Ning; Muneaki Ishijima; Haruka Kaneko; Hidetake Kurihara; Eri Arikawa-Hirasawa; Mitsuaki Kubota; Lizu Liu; Zhuo Xu; Ippei Futami; Anwarjan Yusup; Katsumi Miyahara; Shouyu Xu; Kazuo Kaneko; Hisashi Kurosawa
Journal:  Int Orthop       Date:  2010-06-02       Impact factor: 3.075

5.  Synovial chemokine expression and relationship with knee symptoms in patients with meniscal tears.

Authors:  A Nair; J Gan; C Bush-Joseph; N Verma; M W Tetreault; K Saha; A Margulis; L Fogg; C R Scanzello
Journal:  Osteoarthritis Cartilage       Date:  2015-02-24       Impact factor: 6.576

6.  Associations between biomarkers of joint metabolism, hand osteoarthritis, and hand pain and function: the Johnston County Osteoarthritis Project.

Authors:  Imran Aslam; Irina Perjar; Xiaoyan A Shi; Jordan B Renner; Virginia B Kraus; Yvonne M Golightly; Joanne M Jordan; Amanda E Nelson
Journal:  J Rheumatol       Date:  2014-03-01       Impact factor: 4.666

Review 7.  The role of radiography and MRI for eligibility assessment in DMOAD trials of knee OA.

Authors:  Frank W Roemer; C Kent Kwoh; Daichi Hayashi; David T Felson; Ali Guermazi
Journal:  Nat Rev Rheumatol       Date:  2018-06       Impact factor: 20.543

8.  Running decreases knee intra-articular cytokine and cartilage oligomeric matrix concentrations: a pilot study.

Authors:  Robert D Hyldahl; Alyssa Evans; Sunku Kwon; Sarah T Ridge; Eric Robinson; J Ty Hopkins; Matthew K Seeley
Journal:  Eur J Appl Physiol       Date:  2016-10-03       Impact factor: 3.078

9.  Effects of (-)-epigallocatechin-3-gallate on cyclooxygenase 2, PGE(2), and IL-8 expression induced by IL-1beta in human synovial fibroblasts.

Authors:  Guo-Shu Huang; Ching-Ya Tseng; Chian-Her Lee; Sui-Long Su; Herng-Sheng Lee
Journal:  Rheumatol Int       Date:  2009-09-24       Impact factor: 2.631

10.  Comparison between clinical and ultrasonographic assessment in patients with erosive osteoarthritis of the hands.

Authors:  Athanasios C Koutroumpas; Ioannis S Alexiou; Marianna Vlychou; Lazaros I Sakkas
Journal:  Clin Rheumatol       Date:  2010-01-19       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.